Invega
(Paliperidone)ApprovedSmall molecule
Paliperidone is used to treat schizophrenia and schizoaffective disorder, which are mental health conditions that affect how a person thinks, feels, and behaves. It helps reduce symptoms like hallucinations, delusions, and disorganized thinking.[2] Invega is currently approved and in use across 10 indications[4].[1]
Invega is one of 310 small molecule programs targeting Methamphetamine Dependence. It is currently in Approved.
10
Indications
92
Total Trials
4
Active Trials
309
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Invega
WWim Janssens
Approved
Celexa
AbbViePreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Zocor
OOrganon and Co
Preclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Persantine
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Schizophrenia60 trials
Show 57 more trials
Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00073320·88 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00073320·88 enrolled
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00589914·1,221 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00589914·1,221 enrolledEfficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00101634·518 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00101634·518 enrolledMultidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
Unknown status·CConsorcio Centro de Investigación Biomédica en Red (CIBER)·Phase 4·NCT06060886·244 enrolled
Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study
Not yet recruiting·—·Phase 4·NCT07153835·505 enrolled
Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia
Completed·—·N/A·NCT02918825·100 enrolled
Antipsychotics4 trials
Bipolar Disorder3 trials
Effectiveness2 trials
19 more indications
Psychosis2 trials
Efficacy2 trials
Long-Acting Injection1 trial
Oral1 trial
Schizoaffective Disorder1 trial
Obsessive-Compulsive Disorder1 trial
Post-Traumatic Stress Disorder, PTSD1 trial
Magnetic Resonance Imaging1 trial
Cognitive impairment1 trial
Methamphetamine Dependence1 trial
Suicidality1 trial
Aripiprazole1 trial
Bipolar I Disorder1 trial
ALS1 trial
A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00791349·141 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00791349·141 enrolledMedication1 trial
Efficacy and Safety1 trial
A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00668837·407 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00668837·407 enrolledUnspecified1 trial
Regulatory
FDA Approval Timeline[5]
Aug 26, 2008
INVEGA
NDA NDA021999
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Invega drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Paliperidone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Serotonin 2a (5-Ht2a) Receptor Antagonist; Dopamine D2 Receptor Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- WWim Janssens